Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
6 Articles
6 Articles
Learning to heal was an important part of my MS journey
Day 29 of 31 This is Natasha Quariab’s story: I woke up and tried to move my right leg. Nothing. My heart pounded. This couldn’t be happening. Not here, alone in a snowy Swiss village. The previous day, I had walked to the village square, feeling my leg grow heavier with each step. I convinced […] The post Learning to heal was an important part of my MS journey appeared first on Multiple Sclerosis News Today.
Targeting demyelination and virtual hypoxia with high-dose biotin as a treatment for progressive multiple sclerosis
Progressive multiple sclerosis (MS) is a severely disabling neurological condition, and an effective treatment is urgently needed. Recently, high-dose…
Consensus recommendations on multiple sclerosis management in Australia and New Zealand: part 1
This two-part position statement provides a practical resource for clinicians on current best-practice consensus recommendations for managing adults with MS in the Australian and New Zealand health care settings
Pioneering Prevention: The Next Frontier in Multiple Sclerosis Care
With over 1 million people in Europe living with Multiple Sclerosis and related disorders, a revolutionary shift is taking place in how we approach this challenging condition. For decades, the primary focus has been on treatment and symptom management—but what if we could prevent MS before it begins? This groundbreaking question lies at the heart of the 2025 EMSP Annual Conference in Prague on 16-17 May. Under the theme “Prevention in Multiple S…
CAR-T Cells: A New Frontier in MS Treatment?
Tweet Denison Pedrosa is a Brazilian neurologist with a longstanding interest in multiple sclerosis. He is currently a clinical fellow at Queen Mary University of London, UK, supported by ECTRIMS, with a focus on enhancing access to disease-modifying therapies for multiple sclerosis in developing countries. Chimeric Antigen Receptor T-cell (CAR-T) therapy has garnered significant attention for its potential to revolutionize the treatment of auto…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage